PharmaMar to Host Research and Development Event on April 24, 2017

MADRID, April 6, 2017 /PRNewswire/ --

PharmaMar (MCE: PHM), a leading biopharmaceutical company focused on the discovery and development of innovative marine-derived anticancer drugs, today announced that it will host a Research and Development Event in New York on Monday, April 24th, 2017, from 10:30 am -1:30 pm ET. The event will be hosted by members of PharmaMar's senior management team and will feature presentations from expert speakers. Management and speakers will discuss scientific pipeline including; Phase 3 pivotal study with lurbinectedin (PM1183), current and prospective clinical trials, small-cell lung cancer and hereditary breast cancers, and an overview of Company strategy. Expert guest speakers to include:

• Melinda Telli, MD, Stanford University, Stanford School of Medicine, Stanford, CA
• Martin Forster, MBBS MRCP PhD, UCL Cancer Institute, University College Hospital, London, UK
• Sue Friedman, DVM, Executive Director of Facing Our Risks of Cancer Empowered (FORCE)

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

The presentation will be webcast simultaneously on the calendar section of the Company's Events Calendar page of the website at http://www.pharmamar.com

A webcast replay will be available on the PharmaMar website for 30 days following the call by visiting the Events Calendar page of the company's website at http://www.pharmamar.com.

About PharmaMar  

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS^® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com

MEDIA CONTACTS : Media Relations Manager (Paula Fernández +34-638-79-62-15 – pfalarcon@pharmamar.com ) and Investor Relations (+34-914444500)

SOURCE PharmaMar